下载掌阅APP，畅读海量书库
立即打开
美国妇产科医师学会（ACOG）依据最新的研究证据，结合美国的实际情况，于2017年发布了最新版的《长效可逆避孕—皮下埋植剂和宫内节育器》实践指南，对推进高效长效可逆避孕方法的广泛使用具有积极的作用，也可供我国计划生育工作者参考。我们在临床实际工作中，应紧密结合我国国情，遵循《临床诊疗指南与技术操作规范—计划生育分册》（2017修订版）中的原则，保障妇女的权益和健康。
1.Harper CC，Rocca CH，Thompson KM，et al. Reductions in pregnancy rates in the USA with long-acting reversible contraception：a cluster randomised trial. Lancet，2015，386：562-568.
2.Diedrich JT，Zhao Q，Madden T，et al. Three-year continuation of reversible contraception. Am J Obstet Gynecol，2015，213：662，e1-e8.
3.Heinemann K，Reed S，Moehner S，et al. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices. Contraception，2015，91：274-279.
4.Abraham M，Zhao Q，Peipert JF. Young age，nulliparity，and continuation of long-acting reversible contraceptive methods. Obstet Gynecol，2015，126：823.
5.McNicholas C，Madden T，Secura G，et al. The contraceptive CHOICE project round up：what we did and what we learned. Clin Obstet Gynecol，2014，57：635-643.
6.Steenland MW，Zapata LB，Brahmi D，et al. Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods：a systematic review. Contraception，2013，87：611-624.（Systematic Review）
7.Obijuru L，Bumpus S，Auinger P，et al. Etonogestrel implants in adolescents：experience，satisfaction，and continuation. J Adolesc Health，2016，58：284.
8.Access to contraception. Committee Opinion No. 615. American College of Obstetricians and Gynecologists. Obstet Gynecol，2015，125：250.
9.Increasing access to contraceptive implants and intrauterine devices to reduce unintended pregnancy. Committee Opinion No. 642. American College of Obstetricians and Gynecologists. Obstet Gynecol，2015，126：e44.
10.Phillips SJ，Tepper NK，Kapp N，et al. Progestogen-only contraceptive use among breastfeeding women：a systematic review. Contraception，2016，94：226-252.
11.Braga GC，Ferriolli E，Quintana SM，et al. Immediate postpartum initiation of etonogestrel-releasing implant：A randomized controlled trial on breastfeeding impact. Contraception，2015，92：536-542.
12.Kapp N，Abitbol JL，Mathe H，et al. Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception. Contraception，2015，91：97：1994.
13.Turok DK，Jacobson JC，Dermish AI，et al. Emergency contraception with a copper IUD or oral levonorgestrel：an observational study of 1-year pregnancy rates. Contraception，2014，89：222-228.
14.Wu JP，Pickle S. Extended use of the intrauterine device：a literature review and recommendations for clinical practice. Contraception，2014，89：495.
15.Rowe P，Farley T，Peregoudov A，et al. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device：a 7-year randomized comparative study with the TCu380A. IUD Research Group of the UNDP/UNFPA/WHO/World Bank Special Programme of Research，Development and Research Training in Human Reproduction.Contraception，2016，93：498-506.
16.Creinin MD，Jansen R，Starr RM，et al. Levonorgestrel release rates over 5 years with the Liletta®52-mg intrauterine system. Contraception，2016，94：353-356.
17.Ali M，Akin A，Bahamondes L，et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant：comparison to levonorgestrel-releasing subdermal implant. WHO study group on subdermal contraceptive implants for women. Hum Reprod，2016，31：2491-2498.
18.Grentzer JM，Peipert JF，Zhao Q，et al. Risk-based screening for Chlamydia trachomatis and Neisseria gonorrhoeae prior to intrauterine device insertion. Contraception，2015，92：313-318.
19.Workowski KA，Bolan GA. Sexually transmitted diseases treatment guidelines，2015. Centers for Disease Control and Prevention ［published erratum appears in MMWR Recomm Rep 2015；64：924］. MMWR Recomm Rep，2015，64（RR-03）：1-137.
20.Sordal T，Inki P，Draeby J，et al. Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement：a randomized controlled trial. Obstet Gynecol，2013，121：934-941.